Dominique Costagliola is an expert in Infectiology at Assistance Publique - Hôpitaux de Paris (France). As of October 2026, ScienceLeadR ranks Dominique Costagliola in the top 1% of experts worldwide for HIV Infections. Dominique Costagliola has authored 824 publications, the most recent in 2026, and is an investigator in 39 clinical trials. SLR score: 2,463 (community average: 125). How the SLR is computed.

LeadR Profile

Dominique Costagliola Assistance Publique - Hôpitaux de Paris France
2 463 ScienceLeadR Reputation 2463
Network Map

Infectiology

Subspecialties: Public Health - Pulmonology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Dominique Costagliola, an expert in biostatistics, epidemiology, public health and drug evaluation, is Emeritus Research Director at INSERM's Institut Pierre Louis d'Epidémiologie et de Santé Publique (Sorbonne University, INSERM), where she was Director from 2014 to 2018, then Deputy Director from 2019 to August 2021. She was awarded the Inserm Research Prize in 2013 for her research into HIV/AIDS infection, which began in 1986, and has been a member of the Académie des Sciences since 2017. In 2020 she was awarded the INSERM Grand Prix for her involvement in research into COVID-19.

She studies the hidden parameters of HIV infection (incidence, timing of mother-to-child transmission, cascade, ...), strategies for using antiretroviral treatments, and severe morbidity, particularly cancers and cardiovascular disease in people living with HIV. More recently she has been working in the field of HIV and STI prevention. She is co-leader of a work-package in the EU-Response project, which aims to set up an operational clinical research network in Europe in the field of emerging transmissible diseases.

In addition to her research activities, she is heavily involved in health expertise and decision support for the Ministry of Health and various agencies, as well as in scientific evaluation in France and Europe (including ERC). During the COVID-19 epidemic, she was a member of the Covid-19 Scientific Advisory Board of the ANRS MIE (formerly REACTing) and was heavily involved in the evaluation of research projects on the disease in France and Europe. She was a member of the European High Level Expert Group proposing a roadmap towards stabilisation of the Covid-19 pandemic in the WHO European Region (2021-2023). She is a member of the Scientific Advisory Board of ANRS-MIE. Since June 2017, she has been a member of the Association AIDES and its Board of Directors.

Organizations

Career arc: 1989 - 2026

Source: PubMed

Assistance Publique - Hôpitaux de Paris

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 824

Citations

Citations: 44 671 1st author: 22 Last author: 97 Unique author: 12


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19.
PMID 42863370 — cells, blood, biomedical research, hospital mortality, covid-19, interferon type i, infections
EBioMedicine20260
[Cancer risks in people living with HIV: an incomplete normalization in the era of effective therapy].
PMID 42735344 — neoplasms, hiv, therapeutics
Med Sci (Paris)20260
Accurate health information is the best strategy against misinformation and disinformation: respiratory specialists are on the front line.
PMID 42565799 — research, physical exertion, health literacy, infections
Expert Rev Respir Med20260
Predictors of Cerebral Small-Vessel Disease in Middle-Aged, Virologically Controlled People Living With HIV.
PMID 42434387 — hypertension, risk management, aged, hiv, heart disease risk factors, cerebral small vessel diseases
Open Forum Infect Dis20260
[Accurate health information: A requirement for safety and social cohesion].
PMID 42213970 — safety, social cohesion
Med Sci (Paris)20260

Clinical Studies 39

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 9 Study Director: 6

By phase:

Phase 3 12
Phase 2 10
N/A 7
Phase 4 5
Phase 1/Phase 2 2
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 28
Terminated 9
Active not recruiting 1
Recruiting 1

By type:

Interventional 35
Observational 4

By Monocentric/Multicentric:

monocentric 19
multicentric2to4 5
multicentric5to9 5
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 70

LeadR Networks

Main global connection map